{{Drugbox
 | Verifiedfields =
| Watchedfields =
| verifiedrevid =
| IUPAC_name = 5-[2-Ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-4''H''-pyrazolo[4,3-''d'']pyrimidin-7-one
| image = Homosildenafil.svg
| width = 250

<!--Clinical data-->
| tradename =
| Drugs.com =
| MedlinePlus =
| licence_EU =
| licence_US =
| pregnancy_US =
| legal_status =

<!--Pharmacokinetic data-->
| bioavailability =
| metabolism =
| elimination_half-life =
| excretion =

<!--Identifiers-->
| CAS_number_Ref =
| CAS_number = 642928-07-2
| ATC_prefix = None
| ATC_suffix =
| ChEBI_Ref =
| ChEBI =
| PubChem = 24756844
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0Z3JH0S0QK
| DrugBank_Ref =
| DrugBank =
| ChemSpiderID_Ref =
| ChemSpiderID = 22547032

<!--Chemical data-->
| C=23 | H=32 | N=6 | O=4 | S=1
| molecular_weight = 488.6 g/mol
| smiles = CCCC1=NN(C)C2=C1N=C(NC2=O)C1=CC(=CC=C1OCC)S(=O)(=O)N1CCN(CC)CC1
| StdInChI_Ref =
| StdInChI = 1S/C23H32N6O4S/c1-5-8-18-20-21(27(4)26-18)23(30)25-22(24-20)17-15-16(9-10-19(17)33-7-3)34(31,32)29-13-11-28(6-2)12-14-29/h9-10,15H,5-8,11-14H2,1-4H3,(H,24,25,30)
| StdInChIKey_Ref =
| StdInChIKey = MJEXYQIZUOHDGY-UHFFFAOYSA-N
}}

'''Homosildenafil''' (also known as '''methyl-sildenafil''') is a synthetic [[drug]] which acts as a [[phosphodiesterase inhibitor]].<ref name="vardenafil SAR">{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0197018604000646 | title=Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5) |author1=Jackie D Corbin |author2=Alfreda Beasley |author3=Mitsi A Blount |author4=Sharron H Francis | journal=Neurochemistry International |date=November 2004  | volume=45 | issue=6 | pages=859–863 | doi=10.1016/j.neuint.2004.03.016 | pmid=15312980}}</ref> It is an [[structural analog|analog]] of [[sildenafil]] and [[vardenafil]]. Homosildenafil was first identified as an adulterant in sex enhancement products in 2003 and was more recently detected in dietary supplements.<ref>{{cite journal | url=http://www.tandfonline.com/doi/abs/10.1080/0265203031000121455 | title=Identification of a new analogue of sildenafil added illegally to a functional food marketed for penile erectile dysfunction |author1=M.H. Shin |author2=M.K. Hong |author3=W.S. Kim |author4=Y.J. Lee |author5=Y.C. Jeoung | journal=Food Additives & Contaminants |date=November 2003  | volume=20 | issue=9 | pages=793–796 | pmid=13129773 | doi=10.1080/0265203031000121455}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0731708508006456 | title=Detection of undeclared erectile dysfunction drugs and analogues in dietary supplements by ion mobility spectrometry |author1=Connie M. Gryniewicz |author2=John C. Reepmeyer |author3=John F. Kauffman |author4=Lucinda F. Buhse | journal=Journal of Pharmaceutical and Biomedical Analysis |date=April 2009  | volume=49 | issue=5 | pages=601–606 | doi=10.1016/j.jpba.2008.12.002 | pmid=19150190}}</ref><ref>{{cite web | url=http://www.prnewswire.com/news-releases/advisory---forta-for-men-sex-enhancement-product-recalled-contains-undeclared-drug-287148791.html | title=Advisory - "Forta for Men" sex enhancement product recalled; contains undeclared drug | publisher=PR Newswire | date=2014 | accessdate=28 April 2015}}</ref><ref>{{cite journal | url=http://www.sciencedirect.com/science/article/pii/S0021967305022284 | title=Simultaneous determination of synthetic phosphodiesterase-5 inhibitors found in a dietary supplement and pre-mixed bulk powders for dietary supplements using high-performance liquid chromatography with diode array detection and liquid chromatography–electrospray ionization tandem mass spectrometry |author1=Peng Zoua |author2=Sharon Sze-Yin Ohb |author3=Peiling Houa |author4=Min-Yong Lowb |author5=Hwee-Ling Koh | journal=Journal of Chromatography A |date=February 2006  | volume=1104 | issue=1–2 | pages=113–122 | doi=10.1016/j.chroma.2005.11.103 | pmid=16364350}}</ref>

Homosildenafil has 35% the PDE5 inhibition activity of sildenafil itself with similar selectivity.<ref name="vardenafil SAR"/>

Sildenafil is mainly metabolized by the microsomal [[isozyme]]s [[CYP3A4]] with secondary metabolism by [[CYP2C9]]. The major active metabolite is ''N''-desmethylsildenafil. The plasma level of the equivalent homosildenafil metabolite reaches 40% of sildenafil's bioavailability. The ''N''-desmethyl metabolite is further metabolized, with a half-life of 4 hours.<ref>{{cite web | url=http://www.google.com/patents/WO2001080860A3 | title=Daily treatment for erectile dysfunction using a pde5 inhibitor | date=2002 | accessdate=27 April 2015 |author1=Tejada Inigo Saenz De |author2=Kenneth M Ferguson |author3=John S Whitaker }}</ref><ref>{{cite web | url=http://www.google.com/patents/US20090074796 | title=Pde5 inhibitor compositions and methods for immunotherapy | date=2009 | accessdate=27 April 2015 |author1=Ivan M. Borrello |author2=Paolo Serafini |author3=Kimberly A. Noonan |author4=Vincenzo Bronte }}</ref><ref>{{cite web | url=https://www.google.com/patents/US8497370 | title=Processes for preparing amine salts of sildenafil-analogues and use thereof | date=2013 | accessdate=27 April 2015 | author=Ing-Jun Chen}}</ref><ref>{{cite web | url=https://www.google.com/patents/CN101555512A | title=Preparation method for monoclonal antibody specifically binding vardenafil and analog thereof | date=2009 | accessdate=27 April 2015 | author=杨 许 |author2=郭杰标 |author3=黄志兵}}</ref>

==See also==
* [[Aildenafil]]
* [[Nitrosoprodenafil]]
* [[Sulfoaildenafil]]

==References==
{{reflist|2}}

{{Sexual dysfunction pharmacotherapies}}
{{Phosphodiesterase inhibitors}}

[[Category:Designer drugs]]
[[Category:PDE5 inhibitors]]